Samsung Biologics Co.,Ltd.
207940
株式のランク
#498
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
株価
$1,028.49
時価総額
$47.88B
変化（1日）
-3.67%
変化（1年）
-18.37%
国
KR
取引 Samsung Biologics Co.,Ltd. (207940)
カテゴリー
Healthcare
Samsung Biologics Co.,Ltd.（207940）の発行済株式数
September 2026 時点の発行済株式数 46.61M
Samsung Biologics Co.,Ltd. の最新の財務報告および株価によると、現在の発行済株式数は 46.61M です。December 2024 の終わりには、同社は 46.29M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Samsung Biologics Co.,Ltd.（207940）の発行済株式数の履歴（2014 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 46.61M | 0.79% |
| 2025 | 46.24M | -0.11% |
| 2024 | 46.29M | 0.00% |
| 2023 | 46.29M | 2.05% |
| 2022 | 45.36M | 4.31% |
| 2021 | 43.49M | 0.00% |
| 2020 | 43.49M | 0.00% |
| 2019 | 43.49M | 0.00% |
| 2018 | 43.49M | 0.00% |
| 2017 | 43.49M | 16.56% |
| 2016 | 37.31M | -14.21% |
| 2015 | 43.49M | 0.00% |
| 2014 | 43.49M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 444.79% |
US
|
|
| 396.00M | 749.69% |
US
|
|
| 478.91M | 927.60% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | 33.43% |
NL
|
